Table 1.
Male hormonal contraceptive efficacy trials
| Regimen | N enrolled | N entering/completing efficacy | Pregnancy/Failure rate per 100 couple years | Author/Sponsor |
|---|---|---|---|---|
| Testosterone enanthate weekly injection | 271 | 157/119 | 1 | WHO 1990 |
| 0.8 (0.0 to 4.5) | ||||
| Testosterone enanthate weekly injection | 357 | 268/209 | 4 | WHO 1996 |
| 1.4 (0.4 to 3.7) | ||||
| Testosterone undecanoate monthly injection | 308 | 296/280 | 1 | Gu et al. 2003 |
| 2.3 (0.5 to 4.2) | ||||
| Testosterone undecanoate monthly injection | 1045 | 855/733 | 9 | Gu et al. 2009 |
| 1.1 (0.4 to 1.8) | ||||
| Testosterone implant every 4-6 months + depomedroxyprogesterone acetate injection q 3 months | 55 | 53/28 | 0 | Turner et al. 2003 |
| 0 (0 to 8) | ||||
| Testosterone undecanoate injection + norethisterone enanthate injection every 8 weeks | 320 | 266/111a | 4 | WHO/CONRAD; Behre et al. 2016 |
| 2.2 (0.8 to 5.8) | ||||
| Testosterone + Nestorone® transdermal gel applied daily | ongoing | ongoing | ongoing | NICHD |
a Study stopped early.